Navigation Links
Green & Grow Inc. Secures $6M Series B Funding from Otter Capital
Date:8/27/2014

Austin, TX (PRWEB) August 27, 2014

Green & Grow Inc. (GGI) has raised an additional $6 million in Series B funding and secured Otter Capital as a significant new partner. Otter Capital’s expertise and investment capital will accelerate commercialization of GGI’s Agriplier™ technology, building on recent compelling field trial results across multiple crop types.

“Since our first meeting, we have been impressed with Otter Capital’s knowledge and commitment to the biological product space,” said Alan Sobba, President and CEO of GGI. “We look forward to John’s valuable input and guidance as we work together to complete the commercialization of our exciting technology.”

GGI’s range of Agriplier™ products is based on non-living, non-toxic, microbe derived by-products which contain specific metabolites and stimulants that significantly improve many crops. In the 2013 Independent Professional Seed Association (IPSA) trials, GGI products were the top performing yield enhancement seed treatment products across both corn and soybean, increasing yield over the current commercial seed treatment package. Independent researchers also observe visual improvements in early season plant vigor. Similar results have been demonstrated across a wide range of crops and geographies. The compatibility of Agriplier™ products with both existing chemical and living biological products is also a key differentiator, which will simplify the adoption of the technology.

“I am excited by the potential for selected biologically derived products to make a significant impact in the agriculture industry and the 2013 Green & Grow field trial results illustrate that its technology has already made the critical leap from the lab to achieving success in the field,” said John Pasquesi, Managing Member of Otter Capital and former Chairman of the Board of AgraQuest. “I look forward to working with the GGI team to optimize the delivery of their technology to market and to continue to build the business.”

GGI is currently mid-way through the process of working with industry partners, distributors and end-users to bring the Agriplier™ technology to market. Otter Capital’s investment and experience with this process will significantly assist GGI in selecting the most appropriate route to market and in completing this process.

GGI was represented by Sidley Austin LLP in the transaction, and Otter Capital was represented by Greene Radovsky Maloney Share & Hennigh LLP.

About Otter Capital

Otter Capital has a strong track record developing leading edge agriculture and food production companies. Otter was an early and consistent investor in AgraQuest, a leading biopesticide company. In 2012, Bayer CropScience acquired AgraQuest for $425 million plus earnouts. John Pasquesi previously served as Chairman of the Board of Directors of AgraQuest. More recently, Otter Capital invested alongside Khosla Ventures in a $15 million funding round for BioConsortia, Inc. - an agricultural biotechnology company.

Otter Capital was founded by John Pasquesi to make a variety of private equity investments. Prior to founding Otter Capital in 2001, he was a Managing Director and member of the Executive Committee of Hellman & Friedman LLC - a private equity investment firm. Prior to joining Hellman & Friedman in 1987, Pasquesi was associated with Golder, Thoma & Cressey - a Chicago-based private equity firm.

For more information on Otter Capital, please visit http://www.ottercapital.com.

About Green & Grow Inc.

Green & Grow Inc. (GGI) is dedicated to developing and commercializing biologically derived agricultural products.

Its first range of Agriplier™ products is based on non-living, non-toxic, microbe derived by-products which contain specific metabolites and stimulants that significantly improve many crops.

Agriplier™ products can be easily integrated into multiple seed treatment processes, as well as utilized as a soil amendment. As a non-living product, a key differentiator of Agriplier™ is that it can be easily integrated as an additive solution to both existing chemical and living biological products.

GGI has recently developed a line of OMRI listed products which utilize the Agriplier™ technology. These are being rolled out for ongoing trials with a small number of early adopters.

For more information about GGI and its technologies, please visit http://www.greenandgrow.com.

Agriplier™ is a registered trademark of Green & Grow Inc., a Delaware corporation.

###

Read the full story at http://www.prweb.com/releases/greenandgrow/agriplier/prweb12124330.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Infinity Group Invests US$4.2 M in Green BioTech Company BotanoCap
2. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
3. A New Kind of Medical Thriller in Susy Gage's "Not Easy Being Green," Coming 2015 from Bitingduck Press
4. Cargill’s Dielectric Transformer Oil Made from Natural Esters Wins Presidential Green Chemistry Award
5. Topical BioMedics' Topricin Foot Therapy Cream for Diabetics Now Available in Walgreens' Diabetic Section
6. CareMetx, LLC Combines Operations with Walgreens-Owned Pharma Dynamics, Inc.
7. Green Dot Introduces New Terratek® WC Wood-Plastic Composite Pellets Optimized for Injection Molding and Sheet Extrusion
8. M&G Chemicals Launches Green Revolution in the Polyester Chain
9. Focus on Green Growth and Environmental Sustainability Drives the Global Market for Marine Biotechnology, According to New Report by Global Industry Analysts, Inc.
10. Robert Greenough’s New Book Examines Quantum Reality
11. Shocking News & Research: Boston Scientific, Yingli Green Energy Hold, QUALCOMM, PulteGroup, Regions Financial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017   Sienna Biopharmaceuticals, Inc. , a ... announced that Richard Peterson will join the ... Peterson, who brings more than two decades of ... who is retiring at the end of April but ... Peterson joins Sienna from Novan, Inc., where he served ...
(Date:3/23/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Global Market for Bioproducts Should ... at a CAGR of 8.9%, This research ... into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
Breaking Biology News(10 mins):